RecruitingNCT05240976
Combining two medicines for treatment-resistant schizophrenia research
About this title
Read the official source — NCT05240976Medication studyAges 18–65Taiwan
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- TaichungSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 23, 2022
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 80
- Sponsor
- China Medical University Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Taiwan
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05240976
- Official title
Show the full official title
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Taichung
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is China Medical University Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including NMDAE plus AIFA and NMDAE plus Placebo Cap.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
